Sjögren's Syndrome Symptoms: Dry Eyes, Mouth & More | Johns Hopkins

Sjogren's syndrome can occur independently (primary Sjogren's) or in combination with other autoimmune conditions such as rheumatoid arthritis, scleroderma, lupus, or myositis (secondary Sjogren's). For practical purposes, whether a patient has primary or secondary Sjogren's does not change treatment approaches. However, patients should ask their doctors whether their Sjogren's is primary or secondary, what tests were done to confirm the diagnosis, and whether additional testing is needed to rule out other autoimmune conditions, especially if experiencing ongoing inflammatory joint pain.

Sjögren's syndrome involves glandular dysfunction (dry eyes, dry mouth) and extra-glandular manifestations. Primary Sjögren's involves only glandular manifestations. Secondary Sjögren's is associated with other connective tissue disorders: rheumatoid arthritis, systemic lupus erythematosus, scleroderma, mixed connective tissue disease, or chronic active hepatitis. Viral association is hepatitis C virus. Diagnostic criteria include unstimulated whole salivary secretion <1.5 ml/15 minutes and Schirmer's test <5 mm/5 minutes. Treatment includes artificial tears, cyclosporine (suppresses inflammation and increases secretion), NSAIDs for arthritis, and systemic steroids for severe complications.

Sjögren's syndrome is characterized by lymphocytic infiltration of exocrine glands causing dryness symptoms. Primary Sjögren's occurs alone, while secondary is associated with other autoimmune diseases. Clinical features include sicca syndrome (dry eyes, dry mouth), which can progress to keratoconjunctivitis sicca. Extra-glandular manifestations include arthritis, interstitial lung disease, and renal involvement. Anti-SSA and anti-SSB are characteristic antibodies, with anti-SSA being more specific. The 2016 ACR/EULAR criteria require sicca symptoms plus additional criteria (anti-SSA, Schirmer's test, ocular staining score, salivary gland biopsy) for classification.

Sjögren's syndrome is an autoimmune disease affecting salivary and lacrimal glands, resulting in decreased saliva production (xerostomia) and reduced tear production (xerophthalmia). Primary Sjögren's occurs alone while secondary Sjögren's occurs in association with other autoimmune disorders. Both major and minor salivary glands are affected, with gland enlargement occurring in approximately 50% of patients. Clinical features include oral discomfort from dry mouth, cracked and dry lips, loss of filiform and fungiform papillae on the tongue dorsum, increased risk for caries, periodontal disease, and oral candidiasis. Biopsy reveals characteristic replacement of major salivary glands with lymphocytes and presence of epithelial islands called EPO (epithelial periductal islands). Minor salivary glands show aggregates of lymphocytes surrounding ducts. Approximately 20% of patients experience Raynaud's phenomenon, triggered by cold or emotional stress, characterized by initial pallor from vasoconstriction, followed by cyanosis from decreased blood flow, then hyperemia and redness upon rewarming. About 90% of patients have positive rheumatoid factor, along with anti-Sjögren's syndrome A and anti-Sjögren's syndrome B antibodies. Diagnosis requires two of three components: xerostomia confirmed by salivary flow measurement and biopsy, keratoconjunctivitis sicca confirmed by eye examination, and rheumatoid arthritis. Treatment is symptomatic including NSAIDs for arthritis, corticosteroids and immunosuppressive drugs for severe cases, salivary substitutes (humidifiers, sugarless gum, lemon drops), and artificial tears for ocular protection. Excellent oral hygiene, fluoride use, and frequent dental recare appointments are essential.

Sjögren's syndrome is an autoimmune disorder affecting salivary and lacrimal glands, causing severe dryness in mouth, eyes, and skin. It is not a simple condition but tends to worsen over time. Diagnosis requires symptoms persisting beyond three months. Key diagnostic tests include Schirmer's test for tear production, salivary gland ultrasound, blood tests for ANA and anti-SSA/anti-SSB antibodies, and ESR for inflammation. The syndrome can be primary (occurring alone) or secondary (occurring alongside other autoimmune diseases like rheumatoid arthritis and lupus).

Treatment is primarily symptomatic and supportive. For dry mouth: regular dental care, adequate hydration, chewing dry fruits to stimulate residual gland function, sugar-free gum/lozenges, and artificial saliva as first-line. Muscarinic agonists (pilocarpine 5mg TID, cevimeline 30mg TID) serve as second-line. Severe cases may require hydroxychloroquine. Patients must avoid acidic foods, coffee, alcohol, tobacco, and cannabis. For dry eyes: humidifiers, protective eyewear, artificial tears, topical cyclosporine for moderate disease, and systemic immunosuppression for severe systemic involvement.

Primary Sjögren's syndrome has a good prognosis without reduced life expectancy, though secondary cases depend on the underlying disease. Treatment is symptomatic: xerostomia is managed with saliva substitutes, hydration, sugar-free candies, and oral hygiene; keratoconjunctivitis sicca uses artificial tears, ointments, and secretagogues (pilocarpine causes sweating, cevimeline causes GI effects). Systemic manifestations like arthritis are treated with hydroxychloroquine, methotrexate, corticosteroids, or immunosuppressants (cyclophosphamide, rituximab). Avoidance of smoking and medications causing dryness (diuretics, anticholinergics, antidepressants, antihistamines) is important. Regular monitoring for lymphoma is essential.

Treatment is primarily symptomatic and supportive. For dry eyes: artificial tears and topical cyclosporine 0.05% (suppresses inflammatory tear secretion disruption). For dry mouth: pilocarpine 5mg four times daily and cevimeline 30mg three times daily (acetylcholine derivatives); avoid atropine and decongestants. Oral hygiene with fluoride prevents dental caries. Extra-glandular manifestations (arthritis, vasculitis, pulmonary) respond to immunosuppressive therapy similar to rheumatoid arthritis or SLE. Severe complications require steroids or immunosuppressants. Biological agents (rituximab, belimumab) targeting B-cell pathology treat refractory cases. Vaginal dryness responds to personal lubricants.

Dry eye disease is closely linked to systemic conditions: Sjogren's syndrome (10:1 female predominance, primary vs secondary forms) causes severe complications requiring immunosuppression; neurotrophic keratitis from herpetic infection, diabetes, or surgery requires aggressive treatment despite often absent symptoms; blepharitis involves anterior (staphylococcal) and posterior (meibomian gland) types; rosacea keratitis causes progressive corneal thinning; and ocular graft-versus-host disease affects 40-60% of transplant recipients during chronic phase (6-18 months post-transplant). Effective management follows four principles: moisture replacement (artificial tears, gels, ointments, serum tears); meibomian gland treatment (warm compresses, lid scrubs, erythromycin, doxycycline, IPL); tear loss prevention (contact lenses, moisture chambers, humidifiers); and inflammation control (steroids, cyclosporine, tacrolimus, systemic immunosuppressants).

Treatment is organ-specific. For glandular dysfunction, symptomatic management with artificial tears and sugar-free gum is used; pilocarpine stimulates glands but risks pancreatitis. Immunosuppressive therapy targets extraglandular manifestations: azathioprine, cyclosporine A, and mycophenolate mofetil (especially for lung involvement). Cyclophosphamide treats severe polyneuropathy or CNS involvement. Intravenous immunoglobulins are reserved for refractory cases. Fatigue, caused by circulating antibodies, responds to physical activity. Lymphomas (5% of cases) require ultrasound monitoring.

Lymphoma is a rare but serious complication of Sjögren's disease, resulting from chronic lymphocytic infiltration. All patients require regular monitoring (every 3-6 months or annually) for signs of lymphoma development. While the disease is generally benign (not fatal), lymphoma vigilance is essential. Living near the sea is generally recommended for overall health.

Patients with Sjögren's syndrome face a significantly elevated risk of developing non-Hodgkin lymphoma, particularly mucosa-associated lymphoid tissue (MALT) lymphoma, with studies showing 14-44 times higher risk compared to the general population. This results from years of immune system dysfunction, chronic inflammation, overstimulated B cells, and tissue damage. Warning signs include persistent swollen salivary glands, unexplained fevers, night sweats, rapid weight loss, and lumps in the neck or armpits that don't resolve. Many of these symptoms overlap with normal Sjögren's symptoms, causing delays in diagnosis. Annual blood work, imaging, and lymph node checks are essential for life-long monitoring.

Sjögren's syndrome affects virtually every body system with potentially serious consequences. Gastrointestinal involvement causes abdominal pain and swallowing difficulties. Pulmonary manifestations include interstitial lung disease affecting 20% of patients, causing breathing difficulties and chronic cough. Neurological involvement produces tingling, numbness, burning sensations, and autonomic dysfunction affecting blood pressure and heart rate. Raynaud's phenomenon affects 30% of patients, causing color changes in extremities. Vasculitis can damage vessels throughout the body. Hematologic changes affect 50% of patients, potentially causing anemia or low blood counts. Kidney involvement occurs in 10% of patients. Most critically, Sjögren's carries the highest lymphoma risk among autoimmune diseases, with 5% developing non-Hodgkin's lymphoma. These systemic manifestations require comprehensive monitoring and multidisciplinary care.

Sjögren's syndrome extends beyond glandular involvement to affect multiple organ systems. Common extra-glandular manifestations include arthralgias/arthritis (treated with hydroxychloroquine, methotrexate, prednisolone), Raynaud's phenomenon (nifedipine, cold protection), lymphadenopathy, vasculitis (purpura treated with steroids, cyclophosphamide), kidney disease (interstitial nephritis, stones, impaired concentration, renal tubular acidosis with bicarbonate replacement), and chronic hepatobiliary disease. Non-Hodgkin lymphoma risk is 40 times higher, treated with anti-CD20 therapy plus CHOP chemotherapy. Laboratory findings include leukopenia, anemia, elevated ESR, and autoantibodies (RF, SSA/SSB). Definitive diagnosis requires minor salivary gland biopsy showing lymphocytic infiltration and tissue atrophy. Classification distinguishes primary Sjögren's (isolated disease) from secondary Sjögren's (associated with rheumatoid arthritis, lupus, scleroderma, vasculitis, Hashimoto's, polymyositis, primary biliary cirrhosis, or autoimmune hepatitis).

Sjögren's syndrome manifestations are divided into glandular and extra-glandular, with glandular predominating. Glandular manifestations include oral (xerostomia, dental caries, burning mouth, hoarse voice, buccal/lingual ulcers, parotid enlargement in 60% of primary cases) and ocular (dry eyes, sand sensation, erythema, burning, photophobia from conjunctival epithelial destruction). Other glandular manifestations include respiratory (cough, infections), digestive (esophageal atrophy, gastritis, pancreatitis), and genital (dyspareunia, pruritus). Extra-glandular manifestations occur in 30% of primary patients and include arthralgias (60%), Raynaud's phenomenon (40%), and lymphadenopathy (20%). Lymphoproliferative complications (5%) include non-Hodgkin's B-cell lymphomas and macroglobulinemia.